PT  - JOURNAL ARTICLE
AU  - Christian Vogelberg
AU  - Bernd Brueggenjuergen
AU  - Hartmut Richter
AU  - Marek Jutel
TI  - Real-world adherence of subcutaneous (SCIT) and sublingual (SLIT) pollen AIT: A retrospective analysis in Germany
AID  - 10.1183/13993003.congress-2020.235
DP  - 2020 Sep 07
TA  - European Respiratory Journal
PG  - 235
VI  - 56
IP  - suppl 64
4099  - http://erj.ersjournals.com/content/56/suppl_64/235.short
4100  - http://erj.ersjournals.com/content/56/suppl_64/235.full
SO  - Eur Respir J2020 Sep 07; 56
AB  - Adherence is key to ensure effectiveness of AIT. The aim of the study was to evaluate the real-life adherence to SCIT and SLIT preparations within the prescribing guidelines.We used the IMS LRx® database (IQVIA, Frankfurt, Germany) covering approx. 60% of all German statutory health prescriptions. We compared the adherence of cases (n= 68,586) with an initial AIT prescription in 10/2009-9/2013 (grass) or 6/2010-5/2013 (tree). We analyzed 1 SCIT grass pollen allergoid and 2 grass pollen tablets, 1 SCIT tree pollen allergoid and 2 sublingual tree pollen products. Shares of patients with adherence of ≤1 year, ≤2 years, ≤3 years and >3 years and days on therapy with the respective preparations were descriptively analyzed.61.9% of patients receiving grass pollen SCIT reached the 3rd treatment year, whereas in patients treated with grass pollen tablets adherence up to 3rd year was 29.6/33.7% (dependent on product). For tree pollen treatment adherence up to 3rd year was 60.1% for SCIT and 29.6/33.8% for SLIT. Irrespective of the allergen, the SCIT treatment adherence in children (5-11y) was the highest compared to adolescents (12-17y) or adults (18-50y). In patients on grass AIT the highest number of days on therapy (DoT) was found for the SCIT preparation (mean of 1,034 days); a lower one for grass tablets (means of 488/462 days). For tree pollen AIT, the results for DoTs were comparable to grass pollen AIT.Recent AIT guidelines recommend a minimum of 3 years of AIT to achieve long-term efficacy. Poor adherence is a contraindication for AIT. This real-life analysis of prescription data revealed significant differences in adherence between SCIT and SLIT in favor of SCIT.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 235.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).